Tau protein-binding DNA aptamers with capture/detection and therapeutic utilities in tauopathy-related neurodegenerative disorders

Patent metadata

Field	Value
Publication number	US-10584340-B2
Application number	US-201715720084-A
Country	US
Kind code	B2
Filing date	Sep 29, 2017
Priority date	Sep 29, 2017
Publication date	Mar 10, 2020
Grant date	Mar 10, 2020

Abstract

DNA aptamers that bind to tau protein at its phosphorylatable sites are identified. These disclosed DNA aptamers not only recognize tau at specific phosphorylatable sites, but also demonstrate inhibitory effects on phosphorylation and oligomer formation of tau protein. Molecular probes based on these disclosed DNA aptamers can be used as capture or detection agents to detect the levels of tau and phosphor-tau in cerebrospinal fluid as well as for cell-based or in vivo brain imaging in live animals or human. Compositions comprising these disclosed DNA aptamers can be used to arrest or treat the progression of tauopathy associated neurodegenerative disorders.

First claim

What is claimed is:

1. A DNA aptamer comprising a nucleic acid sequence that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein; wherein the nucleic acid sequence comprises 66 nucleotides and is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

2. A DNA aptamer comprising a nucleic acid sequence that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein; wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11; and wherein the nucleic acid sequence is a truncated fragment of a nucleic acid sequence set forth in SEQ ID NO: 1, and wherein the DNA aptamer is comprised of 100 nucleotides or less.

3. A DNA aptamer comprising a nucleic acid sequence that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein; wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19; and wherein the nucleic acid sequence is a truncated fragment of a nucleic acid sequence set forth in SEQ ID NO: 3, and wherein the DNA aptamer is comprised of 100 nucleotides or less.

4. A DNA aptamer comprising a nucleic acid sequence that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein; wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22; and wherein the nucleic acid sequence is a truncated fragment of a nucleic acid sequence set forth in SEQ ID NO: 4, and wherein the DNA aptamer is comprised of 100 nucleotides or less.

5. A DNA aptamer comprising a nucleic acid sequence that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein; wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25; and wherein the nucleic acid sequence is a truncated fragment of a nucleic acid sequence set forth in SEQ ID NO: 5, and wherein the DNA aptamer is comprised of 100 nucleotides or less.

6. A DNA aptamer comprising a nucleic acid sequence that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein; wherein the nucleic acid sequence is selected from the group consisting of SEQ ID NO: 26 and SEQ ID NO: 27; and wherein the nucleic acid sequence is a truncated fragment of a nucleic acid sequence set forth in SEQ ID NO: 6, and wherein the DNA aptamer is comprised of 100 nucleotides or less.

7. A composition comprising a DNA aptamer that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein, wherein the DNA aptamer comprises a nucleic acid sequence comprising 66 nucleotides and is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO: 6, and SEQ ID NO: 7, and wherein the DNA aptamer is comprised of 100 nucleotides or less.

8. The composition of claim 7 , further comprising a pharmaceutically acceptable carrier or salt.

9. A composition comprising a DNA aptamer that is capable of specifically binding to a tau protein at a phosphorylatable site of the tau protein, wherein the DNA aptamer comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27, and wherein the DNA aptamer is comprised of 100 nucleotides or less.

10. The composition of claim 7 , further comprising a pharmaceutically acceptable excipient.

Assignees

• Univ Florida
• Us Dept Veterans Affairs

Inventors

• Wang Ka W
• Tan Weihong
• Li Xiaowei
• Yadikar Hamad
• Teng I-Ting

Classifications

• G01N2800/2821

  Alzheimer · CPC title

• C12N15/115 Primary

  Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title

• G01N2440/14

  phosphorylation · CPC title

• C12N2310/16

  Aptamers · CPC title

• A61K49/0002

  General or multifunctional contrast agents, e.g. chelated agents · CPC title